[Adjuvant Capecitabine for Residual Disease after Standard Neoadjuvant Chemotherapy Among Patients with Triple-Negative Breast Cancer].

Ishibashi, Yuko; Hirano, Akira; Yukawa, Hiroko; Kitano, Aya; Kodera, Asaka; Fujita, Saki; Hattori, Akinori; Kamimura, Mari; Shiozawa, Shunichi

Ishibashi, Yuko; Hirano, Akira; Yukawa, Hiroko; Kitano, Aya; Kodera, Asaka; Fujita, Saki; Hattori, Akinori; Kamimura, Mari; Shiozawa, Shunichi.

Affiliation

Ishibashi Y; Dept. of Surgery, Breast Surgery, Tokyo Women's Medical University Adachi Medical Center.

Gan To Kagaku Ryoho ; 49(13): 1461-1463, 2022 Dec.

Article in Ja | MEDLINE | ID: mdl-36733102

Subject(s)

Breast Neoplasms; Triple Negative Breast Neoplasms; Humans; Middle Aged; Female; Capecitabine/adverse effects; Triple Negative Breast Neoplasms/drug therapy; Triple Negative Breast Neoplasms/surgery; Neoadjuvant Therapy; Breast Neoplasms/drug therapy; Chemotherapy, Adjuvant/methods; Neoplasm Recurrence, Local/drug therapy; Disease-Free Survival; Antineoplastic Combined Chemotherapy Protocols/therapeutic use

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Triple Negative Breast Neoplasms Limits: Female / Humans / Middle aged Language: Ja Journal: Gan To Kagaku Ryoho Year: 2022 Document type: Article Country of publication: Japan

Search on Google

Add to My VHL

XML

PubMed Links